
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4321350/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Gender discrimination in workplace and depressive symptoms in female employees in South Korea. Journal of Affective Disorders, 2022, 306, 269-275.	2.0	8
2	Association between work-family conflict and depressive symptoms in female workers: An exploration of potential moderators. Journal of Psychiatric Research, 2022, 151, 113-121.	1.5	12
3	Acute Efficacy and Safety of Escitalopram Versus Desvenlafaxine and Vortioxetine in the Treatment of Depression With Cognitive Complaint: A Rater-Blinded Randomized Comparative Study. Psychiatry Investigation, 2022, 19, 268-280.	0.7	5
4	Altered TIMP-3 Levels in the Cerebrospinal Fluid and Plasma of Patients with Alzheimer's Disease. Journal of Personalized Medicine, 2022, 12, 827.	1.1	4
5	Cerebral amyloid accumulation is associated with distinct structural and functional alterations in the brain of depressed elders with mild cognitive impairment. Journal of Affective Disorders, 2021, 281, 459-466.	2.0	14
6	Social participation and depressive symptoms in community-dwelling older adults: Emotional social support as a mediator. Journal of Psychiatric Research, 2021, 137, 589-596.	1.5	68
7	Possible Modulatory Role of ARC Gene Variants in Mood Disorders. Clinical Psychopharmacology and Neuroscience, 2021, 19, 46-52.	0.9	2
8	Standardization of the Korean Version of the Patient Health Questionnaire-4 (PHQ-4). Clinical Psychopharmacology and Neuroscience, 2021, 19, 104-111.	0.9	15
9	Impact of 2D and 3D display watching on EEG power spectra: A standardized low-resolution tomography (sLORETA) study. Signal Processing: Image Communication, 2021, 93, 116151.	1.8	0
10	Clinical Benefit and Utility of Switching to Aripiprazole Once Monthly in Patients with Antipsychotic Polypharmacy or Long Acting Injectable Antipsychotics for Patients with Schizophrenia in Routine Practice: A Retrospective, Observation Study. Clinical Psychopharmacology and Neuroscience, 2021, 19, 233-242.	0.9	1
11	Long working hours and depressive symptoms: moderation by gender, income, and job status. Journal of Affective Disorders, 2021, 286, 99-107.	2.0	16
12	Additional Reduction of Residual Symptoms with Aripiprazole Augmentation in the Patients with Partially Remitted Major Depressive Disorder. Clinical Psychopharmacology and Neuroscience, 2021, 19, 243-253.	0.9	4
13	Importance of connectedness for the management of embitterment and loneliness in the era of COVID-19. Journal of the Korean Medical Association, 2021, 64, 394-399.	0.1	1
14	Consideration of Long-Acting Injectable Antipsychotics for Polypharmacy Regimen in the Treatment of Schizophrenia: Put It on the Table or Not?. Clinical Psychopharmacology and Neuroscience, 2021, 19, 434-448.	0.9	7
15	Changes in Brain Electrical Activity According to Post-traumatic Stress Symptoms in Survivors of the Sewol Ferry Disaster: A 1-year Longitudinal Study. Clinical Psychopharmacology and Neuroscience, 2021, 19, 537-544.	0.9	2
16	Association between high-sensitivity C-reactive protein levels and depression: Moderation by age, sex, obesity, and aerobic physical activity. Journal of Affective Disorders, 2021, 291, 375-383.	2.0	10
17	Brain amyloid accumulation possibly exacerbates concurrent mild cognitive impairment with subthreshold depression in older adults: A 1-year follow-up study. Journal of Affective Disorders, 2021, 295, 93-100.	2.0	2
18	Exploring Hidden Issues in the Use of Antipsychotic Polypharmacy in the Treatment of Schizophrenia. Clinical Psychopharmacology and Neuroscience, 2021, 19, 600-609.	0.9	6

#	Article	IF	CITATIONS
19	Impact of the Coronavirus Disease Pandemic on Mental Health among Local Residents in Korea: a Cross Sectional Study. Journal of Korean Medical Science, 2021, 36, e322.	1.1	9
20	Reduced plasma Fetuin-A is a promising biomarker of depression in the elderly. European Archives of Psychiatry and Clinical Neuroscience, 2020, 270, 901-910.	1.8	8
21	Elevation of plasma soluble amyloid precursor protein beta in Alzheimer's disease. Archives of Gerontology and Geriatrics, 2020, 87, 103995.	1.4	12
22	Validation of the Korean version of the Generalized Anxiety Disorder 7 selfâ€rating Scale. Asia-Pacific Psychiatry, 2020, , e12421.	1.2	25
23	<p>Definition and Identification of Patients with Treatment-Resistant Depression in Real-World Clinical Practice Settings Across Asia</p> . Neuropsychiatric Disease and Treatment, 2020, Volume 16, 2929-2941.	1.0	7
24	<p>Management of Treatment-Resistant Depression in Real-World Clinical Practice Settings Across Asia</p> . Neuropsychiatric Disease and Treatment, 2020, Volume 16, 2943-2959.	1.0	5
25	Normative data and psychometric properties of the Patient Health Questionnaire-9 in a nationally representative Korean population. BMC Psychiatry, 2020, 20, 194.	1.1	33
26	Comparative efficacy and acceptability of pharmacological interventions for the treatment and prevention of delirium: A systematic review and network meta-analysis. Journal of Psychiatric Research, 2020, 125, 164-176.	1.5	33
27	Elevated Cerebrospinal Fluid and Plasma N-Cadherin in Alzheimer Disease. Journal of Neuropathology and Experimental Neurology, 2020, 79, 484-492.	0.9	8
28	Emotional Changes and Protective Factors of Emotional Workers in the Public and Private Sector. Psychiatry Investigation, 2020, 17, 645-653.	0.7	4
29	Effectiveness and Tolerability of Switching to Aripiprazole Once Monthly from Antipsychotic Polypharmacy and/or Other Long Acting Injectable Antipsychotics for Patients with Schizophrenia in Routine Practice: A Retrospective, Observation Study. Clinical Psychopharmacology and Neuroscience, 2020, 18, 153-158.	0.9	9
30	<i>ZNF804A</i> Gene Variants Have a Cross-diagnostic Influence on Psychosis and Treatment Improvement in Mood Disorders. Clinical Psychopharmacology and Neuroscience, 2020, 18, 231-240.	0.9	5
31	Increased plasma complement factor H is associated with geriatric depression. International Psychogeriatrics, 2019, 31, 101-108.	0.6	15
32	Effect of physical activity on suicidal ideation differs by gender and activity level. Journal of Affective Disorders, 2019, 257, 116-122.	2.0	8
33	Association between brain amyloid accumulation and neuropsychological characteristics in elders with depression and mild cognitive impairment. International Journal of Geriatric Psychiatry, 2019, 34, 1907-1915.	1.3	10
34	Usefulness of the 15-item geriatric depression scale (GDS-15) for classifying minor and major depressive disorders among community-dwelling elders. Journal of Affective Disorders, 2019, 259, 370-375.	2.0	70
35	Comparison of the Usefulness of the PHQ-8 and PHQ-9 for Screening for Major Depressive Disorder: Analysis of Psychiatric Outpatient Data. Psychiatry Investigation, 2019, 16, 300-305.	0.7	151
36	Plasma ATG5 is increased in Alzheimer's disease. Scientific Reports, 2019, 9, 4741.	1.6	21

#	Article	IF	CITATIONS
37	Relationships between hand-grip strength, socioeconomic status, and depressive symptoms in community-dwelling older adults. Journal of Affective Disorders, 2019, 252, 263-270.	2.0	43
38	How to approach to suicide prevention. Journal of the Korean Medical Association, 2019, 62, 79.	0.1	5
39	Association of metabolic syndrome and its components with suicidal ideation and depression in adults: A nationally representative sample of the Korean population. Journal of Affective Disorders, 2019, 249, 319-326.	2.0	10
40	Reduced CXCL1/GRO chemokine plasma levels are a possible biomarker of elderly depression. Journal of Affective Disorders, 2019, 249, 410-417.	2.0	12
41	Altered expression of Notch1 in Alzheimer's disease. PLoS ONE, 2019, 14, e0224941.	1.1	34
42	Intimate partner violence and incidence of depression in married women: A longitudinal study of a nationally representative sample. Journal of Affective Disorders, 2019, 245, 305-311.	2.0	11
43	Comorbid Zolpidem Dependence and Over-the-Counter Compound Analgesic Abuse. Clinical Psychopharmacology and Neuroscience, 2019, 17, 323-325.	0.9	5
44	Genes Involved in Neurodevelopment, Neuroplasticity and Major Depression: No Association for <i>CACNA1C, CHRNA7</i> and <i>MAPK1</i> . Clinical Psychopharmacology and Neuroscience, 2019, 17, 364-368.	0.9	12
45	The Potential Utility of Aripiprazole Augmentation for Major Depressive Disorder with Mixed Features Specifier: A Retrospective Study. Clinical Psychopharmacology and Neuroscience, 2019, 17, 495-502.	0.9	12
46	Social capital, socioeconomic status, and depression in community-living elderly. Journal of Psychiatric Research, 2018, 98, 133-140.	1.5	68
47	Hot Genes in Schizophrenia: How Clinical Datasets Could Help to Refine their Role. Journal of Molecular Neuroscience, 2018, 64, 273-286.	1.1	5
48	Tinnitus, depression, and suicidal ideation in adults: A nationally representative general population sample. Journal of Psychiatric Research, 2018, 98, 124-132.	1.5	34
49	Efficacy of antidepressants: bias in randomized clinical trials and related issues. Expert Review of Clinical Pharmacology, 2018, 11, 15-25.	1.3	16
50	Genetic Variants Within Molecular Targets of Antipsychotic Treatment: Effects on Treatment Response, Schizophrenia Risk, and Psychopathological Features. Journal of Molecular Neuroscience, 2018, 64, 62-74.	1.1	3
51	Sickness absence indicating depressive symptoms of working population in South Korea. Journal of Affective Disorders, 2018, 227, 443-449.	2.0	2
52	Neuroplasticity, Neurotransmission and Brain-Related Genes in Major Depression and Bipolar Disorder: Focus on Treatment Outcomes in an Asiatic Sample. Advances in Therapy, 2018, 35, 1656-1670.	1.3	14
53	Emotional labor and depressive mood in service and sales workers: Interactions with gender and job autonomy. Psychiatry Research, 2018, 267, 490-498.	1.7	25
54	Addressing the Side Effects of Contemporary Antidepressant Drugs: A Comprehensive Review. Chonnam Medical Journal, 2018, 54, 101.	0.5	181

#	Article	IF	CITATIONS
55	Relationship of depression, chronic disease, self-rated health, and gender with health care utilization among community-living elderly. Journal of Affective Disorders, 2018, 241, 402-410.	2.0	39
56	Screening for Normal Cognition, Mild Cognitive Impairment, and Dementia with the Korean Dementia Screening Questionnaire. Psychiatry Investigation, 2018, 15, 384-389.	0.7	14
57	A Pharmacogenomic-based Antidepressant Treatment for Patients with Major Depressive Disorder: Results from an 8-week, Randomized, Single-blinded Clinical Trial. Clinical Psychopharmacology and Neuroscience, 2018, 16, 469-480.	0.9	35
58	The Impact of a Single Nucleotide Polymorphism in SIGMAR1 on Depressive Symptoms in Major Depressive Disorder and Bipolar Disorder. Advances in Therapy, 2017, 34, 713-724.	1.3	15
59	Influence of FKBP5 polymorphism and DNA methylation on structural changes of the brain in major depressive disorder. Scientific Reports, 2017, 7, 42621.	1.6	74
60	Comparison between long-acting injectable aripiprazole versus paliperidone palmitate in the treatment of schizophrenia. International Clinical Psychopharmacology, 2017, 32, 235-248.	0.9	19
61	Will the Proteus sensor enhance adherence to aripiprazole or other antipsychotics?. Expert Review of Neurotherapeutics, 2017, 17, 319-321.	1.4	0
62	Investigational dopamine antagonists for the treatment of schizophrenia. Expert Opinion on Investigational Drugs, 2017, 26, 687-698.	1.9	18
63	Genetic Variants Within Key Nodes of the Cascade of Antipsychotic Mechanisms: Effects on Antipsychotic Response and Schizophrenia Psychopathology in a Naturalistic Treatment Setting in Two Independent Korean and Italian Samples. Advances in Therapy, 2017, 34, 1482-1497.	1.3	3
64	Depression and Cognitive Function in Mild Cognitive Impairment: A 1-Year Follow-Up Study. Journal of Geriatric Psychiatry and Neurology, 2017, 30, 280-288.	1.2	16
65	Adjunctive Brexpiprazole as a Novel Effective Strategy for Treating Major Depressive Disorder. Journal of Clinical Psychopharmacology, 2017, 37, 46-53.	0.7	19
66	Modafinil for the treatment of attention-deficit/hyperactivity disorder: A meta-analysis. Journal of Psychiatric Research, 2017, 84, 292-300.	1.5	37
67	VEGFR2 alteration in Alzheimer's disease. Scientific Reports, 2017, 7, 17713.	1.6	42
68	Measurement-based Treatment of Residual Symptoms Using Clinically Useful Depression Outcome Scale: Korean Validation Study. Clinical Psychopharmacology and Neuroscience, 2017, 15, 28-34.	0.9	15
69	Prevalence and Associated Factors of Depression in General Population of Korea: Results from the Korea National Health and Nutrition Examination Survey, 2014. Journal of Korean Medical Science, 2017, 32, 1861.	1.1	101
70	A Korean validation study of the Clinically Useful Anxiety Outcome Scale: Comorbidity and differentiation of anxiety and depressive disorders. PLoS ONE, 2017, 12, e0179247.	1.1	10
71	Assessing reporting quality of randomized controlled trial abstracts in psychiatry: Adherence to CONSORT for abstracts: A systematic review. PLoS ONE, 2017, 12, e0187807.	1.1	28
72	Do Somatic Symptoms Predict the Severity of Depression? A Validation Study of the Korean Version of the Depression and Somatic Symptoms Scale. Journal of Korean Medical Science, 2016, 31, 2002.	1.1	9

#	Article	IF	CITATIONS
73	Perspectives on the Happiness of Community-Dwelling Elderly in Korea. Psychiatry Investigation, 2016, 13, 50.	0.7	20
74	Vilazodone for the Treatment of Depression: An Update. Chonnam Medical Journal, 2016, 52, 91.	0.5	34
75	Second Generation Antipsychotics in the Treatment of Major Depressive Disorder: An Update. Chonnam Medical Journal, 2016, 52, 159.	0.5	48
76	Genes Involved in Neurodevelopment, Neuroplasticity, and Bipolar Disorder: CACNA1C, CHRNA1, and MAPK1. Neuropsychobiology, 2016, 74, 159-168.	0.9	23
77	PDE7B, NMBR and EPM2A Variants and Schizophrenia: A Case-Control and Pharmacogenetics Study. Neuropsychobiology, 2016, 73, 160-168.	0.9	11
78	Precision medicine for psychopharmacology: a general introduction. Expert Review of Neurotherapeutics, 2016, 16, 831-839.	1.4	15
79	Suicidal Ideation Among Korean Elderly: Risk Factors and Population Attributable Fractions. Psychiatry (New York), 2016, 79, 262-281.	0.3	19
80	Characteristics of neurocognitive functions in mild cognitive impairment with depression. International Psychogeriatrics, 2016, 28, 1181-1190.	0.6	15
81	Genome-wide association study of antidepressant response: involvement of the inorganic cation transmembrane transporter activity pathway. BMC Psychiatry, 2016, 16, 106.	1.1	24
82	Second-to-fourth digit length ratio as a measure of harm avoidance. Personality and Individual Differences, 2016, 97, 30-34.	1.6	1
83	Plasma SUMO1 Protein is Elevated inÂAlzheimer's Disease. Journal of Alzheimer's Disease, 2015, 47, 639-643.	1.2	10
84	CACNA1C gene and schizophrenia. Psychiatric Genetics, 2015, 25, 163-167.	0.6	21
85	Optimizing the Use of Aripiprazole Augmentation in the Treatment of Major Depressive Disorder: From Clinical Trials to Clinical Practice. Chonnam Medical Journal, 2015, 51, 66.	0.5	16
86	Vilazodone for the Treatment of Major Depressive Disorder: Focusing on Its Clinical Studies and Mechanism of Action. Psychiatry Investigation, 2015, 12, 155.	0.7	26
87	Posttraumatic Growth and Resilience: Assessment and Clinical Implications. Journal of Korean Neuropsychiatric Association, 2015, 54, 32.	0.2	11
88	Curcumin as a putative antidepressant. Expert Review of Neurotherapeutics, 2015, 15, 269-280.	1.4	36
89	Aripiprazole augmentation versus antidepressant switching for patients with major depressive disorder: A 6-week, randomized, rater-blinded,prospective study. Journal of Psychiatric Research, 2015, 66-67, 84-94.	1.5	30
90	The impact of 3D and 2D TV watching on neurophysiological responses and cognitive functioning in adults. European Journal of Public Health, 2015, 25, 1047-1052.	0.1	7

#	Article	IF	CITATIONS
91	Fibromyalgia diagnosis: a review of the past, present and future. Expert Review of Neurotherapeutics, 2015, 15, 667-679.	1.4	18
92	Vortioxetine: a meta-analysis of 12 short-term, randomized, placebo-controlled clinical trials for the treatment of major depressive disorder. Journal of Psychiatry and Neuroscience, 2015, 40, 174-186.	1.4	53
93	The Influence of AHI1 Variants on the Diagnosis and Treatment Outcome in Schizophrenia. International Journal of Molecular Sciences, 2015, 16, 2517-2529.	1.8	11
94	Pain and Depression: A Neurobiological Perspective of Their Relationship. Psychiatry Investigation, 2015, 12, 1.	0.7	77
95	Quetiapine augmentation for depression. International Clinical Psychopharmacology, 2015, 30, 54-58.	0.9	2
96	Vortioxetine, a multimodal antidepressant for generalized anxiety disorder: A systematic review and meta-analysis. Journal of Psychiatric Research, 2015, 64, 88-98.	1.5	47
97	Five potential therapeutic agents as antidepressants: a brief review and future directions. Expert Review of Neurotherapeutics, 2015, 15, 1015-1029.	1.4	8
98	Criticisms of drugs in early development for the treatment of depression: what can be improved?. Expert Opinion on Investigational Drugs, 2015, 24, 445-453.	1.9	12
99	Schizophrenia relapse and the clinical usefulness of once-monthly aripiprazole depot injection. Neuropsychiatric Disease and Treatment, 2014, 10, 1605.	1.0	8
100	Evidence-Based, Pharmacological Treatment Guideline for Depression in Korea, Revised Edition. Journal of Korean Medical Science, 2014, 29, 468.	1.1	13
101	Metabolic Syndrome and Early Carotid Atherosclerosis in the Elderly. Journal of Atherosclerosis and Thrombosis, 2014, 21, 435-444.	0.9	18
102	Influence of the number and severity of somatic symptoms on the severity of depression and suicidality in community-dwelling elders. Asia-Pacific Psychiatry, 2014, 6, 274-283.	1.2	21
103	Aripiprazole augmentation for major depressive disorder. International Clinical Psychopharmacology, 2014, 29, 116-119.	0.9	8
104	A review of current evidence for acetyl-l-carnitine in the treatment of depression. Journal of Psychiatric Research, 2014, 53, 30-37.	1.5	80
105	Aripiprazole augmentation, antidepressant combination or switching therapy in patients with major depressive disorder who are partial- or non-responsive to current antidepressants: A multi-center, naturalistic study. Journal of Psychiatric Research, 2014, 49, 75-82.	1.5	20
106	Usefulness of the Patient Health Questionnaire-9 for Korean Medical Students. Academic Psychiatry, 2014, 38, 661-667.	0.4	28
107	Lack of influence of rs4680 (COMT) and rs6276 (DRD2) on diagnosis and clinical outcomes in patients with major depression. International Journal of Psychiatry in Clinical Practice, 2014, 18, 97-102.	1.2	19
108	The potential role of atypical antipsychotics for the treatment of posttraumatic stress disorder. Journal of Psychiatric Research, 2014, 56, 72-81.	1.5	27

#	Article	IF	CITATIONS
109	A Meta-Analysis Comparing Open-Label versus Placebo-Controlled Clinical Trials for Aripiprazole Augmentation in the Treatment of Major Depressive Disorder: Lessons and Promises. Psychiatry Investigation, 2014, 11, 371.	0.7	9
110	Abelson Helper Integration Site-1 Gene Variants on Major Depressive Disorder and Bipolar Disorder. Psychiatry Investigation, 2014, 11, 481.	0.7	13
111	Epistatic Interactions between CREB and CREM Variants in Affective Disorder. Psychiatry Investigation, 2014, 11, 200.	0.7	2
112	Atypical antipsychotics as a possible treatment option for irritable bowel syndrome. Expert Opinion on Investigational Drugs, 2013, 22, 565-572.	1.9	16
113	Experiences and barriers to implementation of clinical practice guideline for depression in Korea. BMC Psychiatry, 2013, 13, 150.	1.1	20
114	Do We Need to Consider Ethno-cultural Variation in the Use of Atypical Antipsychotics for Asian Patients with Major Depressive Disorder?. CNS Drugs, 2013, 27, 47-51.	2.7	16
115	Management of Chronic Depressive Patients with Residual Symptoms. CNS Drugs, 2013, 27, 53-57.	2.7	12
116	Second-generation antipsychotics in the treatment of major depressive disorder: current evidence. Expert Review of Neurotherapeutics, 2013, 13, 851-870.	1.4	83
117	Case-control association study of 36 single-nucleotide polymorphisms within 10 candidate genes for major depression and bipolar disorder. Psychiatry Research, 2013, 209, 121-123.	1.7	22
118	Uptake of Web-Based Clinical Resources from the MacArthur Initiative on Depression and Primary Care. Community Mental Health Journal, 2013, 49, 166-171.	1.1	13
119	Investigation of Epistasis Between <i>DAOA</i> and <i>5HTR1A</i> Variants on Clinical Outcomes in Patients with Schizophrenia. Genetic Testing and Molecular Biomarkers, 2013, 17, 504-507.	0.3	8
120	Dilemma for enhancing psychiatrists' adherence to guideline (evidence)-based practice. Expert Review of Neurotherapeutics, 2013, 13, 751-754.	1.4	3
121	Alexithymia and low cooperativeness are associated with suicide attempts in male military personnel with adjustment disorder: A case–control study. Psychiatry Research, 2013, 205, 220-226.	1.7	24
122	Oxidative/nitrosative stress and antidepressants: Targets for novel antidepressants. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2013, 46, 224-235.	2.5	124
123	Evidence for the Benefits of Nonantipsychotic Pharmacological Augmentation in the Treatment of Depression. CNS Drugs, 2013, 27, 21-27.	2.7	18
124	Asenapine, Blonanserin, Iloperidone, Lurasidone, and Sertindole. Clinical Neuropharmacology, 2013, 36, 223-238.	0.2	23
125	Aripiprazole augmentation for treatment of patients with chronic or recurrent major depressive disorder. International Clinical Psychopharmacology, 2013, 28, 322-329.	0.9	11
126	Investigation of possible epistatic interactions between <i>GRIA2</i> and <i>GRIA4</i> variants on clinical outcomes in patients with major depressive disorder. Journal of International Medical Research, 2013, 41, 809-815.	0.4	7

#	Article	IF	CITATIONS
127	Increased Carotid Intima-Media Thickness and Plasma Homocysteine Levels Predict Cardiovascular and All-Cause Death: A Population-Based Cohort Study. European Neurology, 2013, 70, 1-5.	0.6	16
128	Miniâ€Mental Status Examination as predictors of mortality in the elderly. Acta Psychiatrica Scandinavica, 2013, 127, 298-304.	2.2	50
129	Distressed personality without a partner enhances the risk of depression in patients with coronary heart disease. Asia-Pacific Psychiatry, 2013, 5, 284-292.	1.2	4
130	A review of current evidence for vilazodone in major depressive disorder. International Journal of Psychiatry in Clinical Practice, 2013, 17, 160-169.	1.2	31
131	Oral scopolamine augmentation for major depression. Expert Review of Neurotherapeutics, 2013, 13, 19-21.	1.4	4
132	Sensitivity of cognitive tests in four cognitive domains in discriminating MDD patients from healthy controls: a meta-analysis. International Psychogeriatrics, 2013, 25, 1543-1557.	0.6	65
133	Diagnosis and treatment of dementia in primary care. Journal of the Korean Medical Association, 2013, 56, 1104.	0.1	15
134	Evidence-Based Korean Pharmacological Treatment Guideline for Depression, Revised Edition (I) : Initial Choice of Antidepressant Treatment. Journal of Korean Neuropsychiatric Association, 2013, 52, 253.	0.2	4
135	Evidence-Based Korean Pharmacological Treatment Guideline for Depression, Revised Edition (III) : Dose Increment, Switching, Combination, and Augmentation Strategy in Antidepressant Therapy. Journal of Korean Neuropsychiatric Association, 2013, 52, 386.	0.2	2
136	Distinguishing Quantitative Electroencephalogram Findings between Adjustment Disorder and Major Depressive Disorder. Psychiatry Investigation, 2013, 10, 62.	0.7	20
137	A Normative Study of Lexical Verbal Fluency in an Educationally-Diverse Elderly Population. Psychiatry Investigation, 2013, 10, 346.	0.7	18
138	Evidence-Based Korean Pharmacological Treatment Guideline for Depression, Revised Edition (II) : Antidepressant Efficacy Compared with Placebo, Difference in Efficacy of Antidepressants, and Appropriate Time of Efficacy Judgment in Antidepressant Therapy. Journal of Korean Neuropsychiatric Association, 2013, 52, 372.	0.2	2
139	Changes in sexual function and gonadal axis hormones after switching to aripiprazole in male schizophrenia patients. International Clinical Psychopharmacology, 2012, 27, 177-183.	0.9	15
140	Combination Treatment With Aripiprazole and Valproic Acid for Acute Mania. Clinical Neuropharmacology, 2012, 35, 97-102.	0.2	9
141	Can botulinum toxin improve mood in depressed patients?. Expert Review of Neurotherapeutics, 2012, 12, 1049-1051.	1.4	10
142	Temperament and Character of Young Male Conscripts With Adjustment Disorder. Journal of Nervous and Mental Disease, 2012, 200, 973-977.	0.5	10
143	Interactive influences of demographics on the Mini-Mental State Examination (MMSE) and the demographics-adjusted norms for MMSE in elderly Koreans. International Psychogeriatrics, 2012, 24, 642-650.	0.6	17
144	Case–control association study of 14 variants of CREB1, CREBBP and CREM on diagnosis and treatment outcome in major depressive disorder and bipolar disorder. Psychiatry Research, 2012, 198, 39-46.	1.7	23

#	Article	IF	CITATIONS
145	Case–control association study ofGRIA1,GRIA2andGRIA4polymorphisms in bipolar disorder. International Journal of Psychiatry in Clinical Practice, 2012, 16, 18-26.	1.2	8
146	Association of chronic divalproex sodium use and brain atrophy in Alzheimer's disease. Expert Review of Neurotherapeutics, 2012, 12, 155-158.	1.4	0
147	DAOA Variants on Diagnosis and Response to Treatment in Patients with Major Depressive Disorder and Bipolar Disorder. Journal of International Medical Research, 2012, 40, 258-265.	0.4	5
148	Influence of GRIA1, GRIA2 and GRIA4 polymorphisms on diagnosis and response to antipsychotic treatment in patients with schizophrenia. Neuroscience Letters, 2012, 506, 170-174.	1.0	15
149	Possible influence of CREB1, CREBBP and CREM variants on diagnosis and treatment outcome in patients with schizophrenia. Neuroscience Letters, 2012, 508, 37-41.	1.0	9
150	Bright light therapy as an adjunctive treatment with risperidone in patients with delirium: a randomized, open, parallel group study. General Hospital Psychiatry, 2012, 34, 546-551.	1.2	31
151	Symptom severity and attitudes toward medication: Impacts on adherence in outpatients with schizophrenia. Schizophrenia Research, 2012, 134, 226-231.	1.1	105
152	Influence of <i>BDNF</i> Variants on Diagnosis and Response to Treatment in Patients with Major Depression, Bipolar Disorder and Schizophrenia. Neuropsychobiology, 2012, 65, 1-11.	0.9	53
153	Characteristics of Type D personality in Korean adolescents. European Child and Adolescent Psychiatry, 2012, 21, 699-706.	2.8	9
154	Influence of GRIA1, GRIA2 and GRIA4 polymorphisms on diagnosis and response to treatment in patients with major depressive disorder. European Archives of Psychiatry and Clinical Neuroscience, 2012, 262, 305-311.	1.8	30
155	Case–control association study for 10 genes in patients with schizophrenia: influence of 5HTR1A variation rs10042486 on schizophrenia and response to antipsychotics. European Archives of Psychiatry and Clinical Neuroscience, 2012, 262, 199-205.	1.8	31
156	Association Between Visceral Obesity and Sarcopenia and Vitamin D Deficiency in Older Koreans: The Ansan Geriatric Study. Journal of the American Geriatrics Society, 2012, 60, 700-706.	1.3	56
157	Attitudes on clinical research participation of community living elders in <scp>K</scp> orea. Asia-Pacific Psychiatry, 2012, 4, 168-173.	1.2	1
158	Standardization of the Korean Version of the Posttraumatic Embitterment Disorder Self-Rating Scale. Psychiatry Investigation, 2012, 9, 368.	0.7	23
159	Paliperidone. Clinical Drug Investigation, 2012, 32, 497-512.	1.1	8
160	DAOAvariants and schizophrenia: Influence on diagnosis and treatment outcomes. International Journal of Psychiatry in Clinical Practice, 2011, 15, 303-310.	1.2	4
161	Aripiprazole treatment for patients with schizophrenia: from acute treatment to maintenance treatment. Expert Review of Neurotherapeutics, 2011, 11, 1541-1552.	1.4	12
162	Cholinesterase Inhibitors for Alzheimer Disease: Do They Provide More Than Symptomatic Benefits?. American Journal of Geriatric Psychiatry, 2011, 19, 266-273.	0.6	7

#	Article	IF	CITATIONS
163	Region and frequency specific changes of spectral power in Alzheimer's disease and mild cognitive impairment. Clinical Neurophysiology, 2011, 122, 2169-2176.	0.7	63
164	DRD2/ANKK1 Taql A polymorphism affects corticostriatal activity in response to negative affective facial stimuli. Behavioural Brain Research, 2011, 223, 36-41.	1.2	8
165	Paliperidone-associated atypical neuroleptic malignant syndrome: A case report. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2011, 35, 650-651.	2.5	12
166	Zonisamide produces weight loss in psychotropic drug-treated psychiatric outpatients. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2011, 35, 1918-1921.	2.5	7
167	Influence of TPH2 variants on diagnosis and response to treatment in patients with major depression, bipolar disorder and schizophrenia. Psychiatry Research, 2011, 189, 26-32.	1.7	42
168	Do we need more than one antidepressant for patients with major depressive disorder?. Expert Review of Neurotherapeutics, 2011, 11, 1561-1564.	1.4	8
169	Assessment of the Type D Personality Construct in the Korean Population: A Validation Study of the Korean DS14. Journal of Korean Medical Science, 2011, 26, 116.	1.1	101
170	Depression, suicide, and Korean society. Journal of the Korean Medical Association, 2011, 54, 358.	0.1	13
171	Depression Is Associated with Sarcopenia, Not Central Obesity, in Elderly Korean Men. Journal of the American Geriatrics Society, 2011, 59, 2062-2068.	1.3	101
172	Paliperidone in the treatment of delirium: results of a prospective open-label pilot trial. Acta Neuropsychiatrica, 2011, 23, 179-183.	1.0	8
173	Identification of peripheral inflammatory markers between normal control and Alzheimer's disease. BMC Neurology, 2011, 11, 51.	0.8	58
174	Association of sedative–hypnotic medications with suicidality. Expert Review of Neurotherapeutics, 2011, 11, 345-349.	1.4	7
175	Safety and Tolerability of Lamotrigine. Clinical Neuropharmacology, 2011, 34, 39-47.	0.2	53
176	Available therapies and current management of fibromyalgia: Focusing on pharmacological agents. Drugs of Today, 2011, 47, 539.	0.7	16
177	Plasma Carbonic Anhydrase II protein is Elevated in Alzheimer's Disease. Journal of Alzheimer's Disease, 2010, 21, 939-945.	1.2	35
178	Lack of association between antisperm antibodies and language dysfunction in Alzheimer's disease. Archives of Gerontology and Geriatrics, 2010, 50, 338-340.	1.4	6
179	Paroxetine mesylate: comparable to paroxetine hydrochloride?. Expert Opinion on Pharmacotherapy, 2010, 11, 185-193.	0.9	9
180	Brain-derived neurotrophic factor gene polymorphisms and mirtazapine responses in Koreans with major depression. Journal of Psychopharmacology, 2010, 24, 1755-1763.	2.0	45

#	Article	IF	CITATIONS
181	Low Levels of Plasma Agmatine in the Metabolic Syndrome. Metabolic Syndrome and Related Disorders, 2010, 8, 21-24.	0.5	6
182	Serum Homocysteine and Folate Levels are Associated With Late-life Dementia in a Korean Population. Osong Public Health and Research Perspectives, 2010, 1, 17-22.	0.7	6
183	History of early abuse as a predictor of treatment response in patients with fibromyalgia: A post-hoc analysis of a 12-week, randomized, double-blind, placebo-controlled trial of paroxetine controlled release. World Journal of Biological Psychiatry, 2009, 10, 435-441.	1.3	11
184	Study design and methods of the Ansan Geriatric Study (AGE study). BMC Neurology, 2009, 9, 10.	0.8	35
185	The cutoff values of visceral fat area and waist circumference for identifying subjects at risk for metabolic syndrome in elderly Korean: Ansan Geriatric (AGE) cohort study. BMC Public Health, 2009, 9, 443.	1.2	59
186	Thyroid hormones affect recovery from depression during antidepressant treatment. Psychiatry and Clinical Neurosciences, 2009, 63, 305-313.	1.0	19
187	Adiposity parameters and cognitive function in the elderly: Application of "Jolly Fat―hypothesis to cognition. Archives of Gerontology and Geriatrics, 2009, 49, e133-e138.	1.4	45
188	Effectiveness of antidepressant treatments in pre-menopausal versus post-menopausal women: A pilot study on differential effects of sex hormones on antidepressant effects. Biomedicine and Pharmacotherapy, 2009, 63, 228-235.	2.5	67
189	Duloxetine: An emerging evidence for fibromyalgia. Biomedicine and Pharmacotherapy, 2009, 63, 69-71.	2.5	5
190	The impact of the CONSORT statement on reporting of randomized clinical trials in psychiatry. Contemporary Clinical Trials, 2009, 30, 116-122.	0.8	58
191	Psychometric Properties of the Patient Health Questionnaire–15 (PHQ–15) for Measuring the Somatic Symptoms of Psychiatric Outpatients. Psychosomatics, 2009, 50, 580-585.	2.5	21
192	Pregabalin augmentation of antidepressants in patients with accident-related posttraumatic stress disorder: an open label pilot study. International Clinical Psychopharmacology, 2009, 24, 29-33.	0.9	21
193	Effects of CYP2D6 and CYP3A5 Genotypes on the Plasma Concentrations of Risperidone and 9-Hydroxyrisperidone in Korean Schizophrenic Patients. Journal of Clinical Psychopharmacology, 2009, 29, 272-277.	0.7	42
194	Methylphenidate Extended Release (OROS MPH) for the Treatment of Antidepressant-Related Sexual Dysfunction in Patients With Treatment-Resistant Depression. Clinical Neuropharmacology, 2009, 32, 85-88.	0.2	12
195	Milnacipran. Clinical Neuropharmacology, 2009, 32, 355-363.	0.2	39
196	Psychometric Properties of the Patient Health Questionnaire-15 (PHQ-15) for Measuring the Somatic Symptoms of Psychiatric Outpatients. Psychosomatics, 2009, 50, 580-585.	2.5	88
197	Desvenlafaxine, a serotonin-norepinephrine uptake inhibitor for major depressive disorder, neuropathic pain and the vasomotor symptoms associated with menopause. Current Opinion in Investigational Drugs, 2009, 10, 75-90.	2.3	10
198	Effects of Methylphenidate and Bupropion on DHEA-S and Cortisol Plasma Levels in Attention-deficit Hyperactivity Disorder. Child Psychiatry and Human Development, 2008, 39, 201-209.	1.1	37

#	Article	IF	CITATIONS
199	Delirium: Where do we stand?. Current Psychiatry Reports, 2008, 10, 240-248.	2.1	7
200	Delirium: Underrecognized and undertreated. Current Treatment Options in Neurology, 2008, 10, 386-395.	0.7	12
201	An adaptation of the Korean mini-mental state examination (K-MMSE) in elderly Koreans: Demographic influence and population-based norms (the AGE study). Archives of Gerontology and Geriatrics, 2008, 47, 302-310.	1.4	231
202	Awareness of putative risk factors for Alzheimer's disease among elderly Koreans. Acta Neuropsychiatrica, 2008, 20, 20-24.	1.0	5
203	Attitudes of patients and family members towards implantable psychiatric medication. Schizophrenia Research, 2008, 105, 279-286.	1.1	9
204	Does Neurotropin-3 Have a Therapeutic Implication in Major Depression?. International Journal of Neuroscience, 2008, 118, 1515-1522.	0.8	28
205	No association between the brain-derived neurotrophic factor gene Val66Met polymorphism and tardive dyskinesia in schizophrenic patients. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2008, 32, 1545-1548.	2.5	23
206	Manganese superoxide dismutase gene Ala–9Val polymorphism might be related to the severity of abnormal involuntary movements in Korean schizophrenic patients. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2008, 32, 1844-1847.	2.5	28
207	Does minocycline have antidepressant effect?. Biomedicine and Pharmacotherapy, 2008, 62, 308-311.	2.5	98
208	Validation of the Patient Health Questionnaire-9 Korean version in the elderly population: the Ansan Geriatric study. Comprehensive Psychiatry, 2008, 49, 218-223.	1.5	344
209	Paroxetine: safety and tolerability issues. Expert Opinion on Drug Safety, 2008, 7, 783-794.	1.0	51
210	Val158Met Polymorphism in the Catechol- <i>O</i> -Methyltransferase ( <i>COMT)</i> Gene Is Not Associated with Tardive Dyskinesia in Schizophrenia. Neuropsychobiology, 2008, 57, 22-25.	0.9	18
211	The relationship between fibromyalgia and major depressive disorder: a comprehensive review. Current Medical Research and Opinion, 2008, 24, 2359-2371.	0.9	52
212	Reply to Dr Ng's Comments on "A Randomized, Double-Blind, Placebo-Controlled Trial of Augmentation With An Extended Release Formulation of Methylphenidate in Outpatients With Treatment-Resistant Depression". Journal of Clinical Psychopharmacology, 2008, 28, 117-118.	0.7	0
213	Mental health economics, health service provision, and the practice of geriatric psychiatry. Current Opinion in Psychiatry, 2008, 21, 546-550.	3.1	7
214	History of Depressive and Anxiety Disorders and Paroxetine Response in Patients With Irritable Bowel Syndrome. Primary Care Companion To the Journal of Clinical Psychiatry, 2008, 10, 368-375.	0.6	8
215	Fatigue as a core symptom in major depressive disorder: overview and the role of bupropion. Expert Review of Neurotherapeutics, 2007, 7, 1251-1263.	1.4	74
216	Low plasma BDNF is associated with suicidal behavior in major depression. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2007, 31, 78-85.	2.5	248

#	Article	IF	CITATIONS
217	Reply to Comments on "Low Plasma BDNF is associated with Suicidal Behavior in Major Depressionâ€ <del>,</del> Progress in Neuro-Psychopharmacology and Biological Psychiatry 2006. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2007, 31, 580-581.	2.5	0
218	Characteristics and clinical correlates of restless legs syndrome in schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2007, 31, 1078-1083.	2.5	58
219	Usefulness of long-acting injectable risperidone during 12-month maintenance therapy of bipolar disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2007, 31, 1219-1223.	2.5	27
220	A Glu487Lys polymorphism in the gene for mitochondrial aldehyde dehydrogenase 2 is associated with myocardial infarction in elderly Korean men. Clinica Chimica Acta, 2007, 382, 43-47.	0.5	87
221	Plasma Homocysteine Is Associated with the Risk of Mild Cognitive Impairment in an Elderly Korean Population ,. Journal of Nutrition, 2007, 137, 2093-2097.	1.3	58
222	Usefulness of Beck Depression Inventory (BDI) in the Korean elderly population. International Journal of Geriatric Psychiatry, 2007, 22, 218-223.	1.3	122
223	Carotid intimaâ€media thickness in Parkinson's disease. Movement Disorders, 2007, 22, 2446-2449.	2.2	20
224	Possible association between G-protein β3 subunit C825T polymorphism and antipsychotic-induced restless legs syndrome in schizophrenia. Acta Neuropsychiatrica, 2007, 19, 351-356.	1.0	12
225	Morbidity and related factors among elderly people in South Korea: results from the Ansan Geriatric (AGE) cohort study. BMC Public Health, 2007, 7, 10.	1.2	63
226	Increased plasma nitric oxide level associated with suicide attempt in depressive patients. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2006, 30, 1091-1096.	2.5	93
227	Mental Health of Healthcare Workers who Experience Needlestick and Sharps Injuries. Journal of Occupational Health, 2006, 48, 474-479.	1.0	79
228	No borna disease virus-specific RNA detected in blood of race horses and jockeys. Acta Neuropsychiatrica, 2006, 18, 177-180.	1.0	2
229	No difference in stroke knowledge between Korean adherents to traditional and western medicine – the AGE study: an epidemiological study. BMC Public Health, 2006, 6, 153.	1.2	44
230	Long-term treatment with long-acting risperidone in Korean patients with schizophrenia. Human Psychopharmacology, 2006, 21, 399-407.	0.7	23
231	Increased Plasma Nitric Oxide Metabolites in Suicide Attempters. Neuropsychobiology, 2006, 53, 127-132.	0.9	74
232	No association between the tryptophan hydroxylase gene polymorphism and major depressive disorders and antidepressant response in a Korean population. Psychiatric Genetics, 2005, 15, 299-301.	0.6	38
233	Antipsychotics and dopamine transporter gene polymorphisms in delirium patients. Psychiatry and Clinical Neurosciences, 2005, 59, 183-188.	1.0	42
234	Latency of auditory P300 correlates with self-control as measured by the Sixteen Personality Factor Questionnaire. Psychiatry and Clinical Neurosciences, 2005, 59, 418-424.	1.0	1

#	Article	IF	CITATIONS
235	G-Protein β <sub>3</sub> Subunit C825T Polymorphism Tends to Be Associated with Seasonal Variation in Young Male College Students. Neuropsychobiology, 2005, 52, 135-139.	0.9	19
236	Treatment in risperidone-induced amenorrhoea. International Journal of Psychiatry in Clinical Practice, 2005, 9, 29-34.	1.2	7
237	High concentrations of plasma brain-derived neurotrophic factor in methamphetamine users. Neuroscience Letters, 2005, 388, 112-115.	1.0	82
238	Satisfaction of patients and caregivers with long-acting injectable risperidone and oral atypical antipsychotics. Primary Care and Community Psychiatry, 2005, 10, 119-124.	0.4	4
239	Association between Norepinephrine Transporter Gene Polymorphism and Major Depression. Neuropsychobiology, 2004, 49, 174-177.	0.9	66
240	Association between a G-protein β3 subunit gene polymorphism and the symptomatology and treatment responses of major depressive disorders. Pharmacogenomics Journal, 2004, 4, 29-33.	0.9	103
241	Th1, Th2 and Th3 cytokine alteration in schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2004, 28, 1129-1134.	2.5	164
242	T-helper types 1, 2, and 3 cytokine interactions in symptomatic manic patients. Psychiatry Research, 2004, 129, 267-272.	1.7	90
243	A Double-Blind Trial of Risperidone and Haloperidol for the Treatment of Delirium. Psychosomatics, 2004, 45, 297-301.	2.5	249
244	Borna disease virus and deficit schizophrenia. Acta Neuropsychiatrica, 2003, 15, 262-265.	1.0	7
245	The plasma levels of interleukin-12 in schizophrenia, major depression, and bipolar mania: effects of psychotropic drugs. Molecular Psychiatry, 2002, 7, 1107-1114.	4.1	203
246	Psychiatric Symptoms Reported by International Peacekeeping Personnel in the Western Sahara Desert. Journal of Nervous and Mental Disease, 2001, 189, 858-860.	0.5	33